7

RCE/1617

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ONTINUED EXAMINATION (RCE) TRANSMITTAL

TRANSMITTAL

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Stop RCE

collection of information unless it displays a valid ONB control number.				
Application Number	09/838,649	H		
Filing Date	April 19, 2001	3	ڀ	
First Named Inventor	Cioca	Ä	Ž	
Art Unit	1617.	田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田	22	
Examiner Name	Wells, Lauren Q.	1600	2004	
Attorney Docket Number	99.25US	/29(4	

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered				
and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such				
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.				
I. Consider the arguments in the Appeal Brief or Reply Brief previously filed on				
ii. 🗖 Other				
b. Enclosed				
i. ⊠ Amendment/Reply iii. ⊠ Information Disclosure Statement (IDS) ii. □ Affidavit(s)/Declaration(s) iv. □ Other				
2. Miscellaneous				
a. Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for				
a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required) b. □ Other				
3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.				
a. The Director is hereby authorized to charge the following fees, or credit any overpayments, to				
Deposit Account No. 05-1320 i. RCE fee required under 37 CFR 1.17(e) .				
ii. Extension of time fee (37 CFR 1.17(e) . 01/16/2004 AWDNDAF1 000000007 051320 09838649				
iii. Other 01 FC:1801 770,00 pa				
b. Check in the amount of \$ enclosed				
C. Payment by credit card (Form PTO-2038 enclosed)				
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED				
Name (Print/Type) Dorene M. Price Registration No. (Attorney/Agent) 43,018				
Signature Date January 12, 2004				
CERTIFICATE OF MAILING OR TRANSMISSION				
hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.				
Name (Print / Type) FRANCINE MAGEE				
Signature Date January 12, 2004				

	MAILING BY FIRST CLAS	SS MAIL (37 CFR 1.8)	Docket No.	
Applicant(s): Cioca et al	•		99.25US	
Serial No.	Filing Date	Examiner	Group Art Unit	
09/837,649	April 19, 2001	Wells, Lauren Q.	1617	
/ ()	nicrobials in Structured Water		A	
15 2004 E			CCE	
MAL			TECH CENTER TO 2004	<u>.</u>
PATENT & TRACEPE		·	CEAN OZODA	'
			THE TANK OF	
I hereby certify that this	S COM. RCE trans. Ext Time.	Amend (8pp), IDS trans, PTO		
		(Identify type of correspondence)		
is being deposited wi	ith the United States Postal Se	ervice as first class mail in	an envelope addressed to:	
Commissioner for Pate	ents, P.O. Box 1450, Alexandria,	VA 22313-1450 on	January 12, 2004	
			(Date)	
		FRANCINE		
	,	(Typed or Printed Name of Person	Mailing Correspondence)	
		(Signature of Person Mailin	Magee	
		V-10	* ·····	
	Note: Each paper must ha	we its own certificate of mailing.		
				

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))		111	Docket No. 99.25US	
In Re Application: (Cioca, et al.			
Serial No.	Filing Date	Examiner	Group Art Unit	
09/838,649	April 19, 2001	Wells, Lauren Q.	1617	
·	·	ment of Fee		
as described belo ☐ Charge tl ☐ Credit an	nount of is atta ereby authorized to charge and c	ects to pay the fee set forth in 37 CFR 1.1 ached. redit Deposit Account No.	<i>(</i> (p))	
	Fransmission by Facsimile*	Certificate of Mailing by	First Class Mail	
I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F: (Date)		I certify that this document and fee is being deposited on January 13, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.		
	Signature Signature of Person Mailing Correspondence FRANCINE MAGEE		ing Correspondence	
Typed or Printed N	Typed or Printed Name of Person Signing Certificate Typed or Printed Name of Person Mailing Certificate		n Mailing Certificate	
deposit account.	y only be used if paying by Granture 018)	Dated: January 12, 2004		
cc:				

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 99.25US		
In Re Application Of: Cioca, et al.					
Serial No.	Serial No. Filing Date Examiner		Group Art Unit		
09/838,649	April 19, 2001	Wells, Lauren Q.	1617		
Title: Stable Antimicrob	oials in Structured Water				
	Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450				
	37 C	FR 1.97(b)			
1. A The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.					
	37 C	FR 1.97(c)			
2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:					
☐ the statement specified in 37 CFR 1.97(e);					
OR					
☐ the fee set forth in 37 CFR 1.17(p).					